Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms

被引:0
|
作者
Deng Bo [1 ]
Jia Liqun [1 ]
Tan Huangying [1 ]
Lou Yanni [1 ]
Li Xue [1 ]
Li Yuan [1 ]
Yu Lili [1 ]
机构
[1] China Japan Friendship Hosp, Integrat Oncol Dept, Beijing 100029, Peoples R China
关键词
UGT1A1; enzyme; Diarrhea; Irinotecan; Shengjiangxiexin decoction; COLORECTAL-CANCER PATIENTS; INDUCED DIARRHEA; OXALIPLATIN; UGT1A;
D O I
暂无
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
OBJECTIVE: To evaluate the efficacy of Shengjiangxiexin decoction (SXD), prepared with a formula from Traditional Chinese Medicine (TCM), in reducing irinotecan-induced hematological and gastrointestinal toxicities in patients with UDP-glucuronosyltransferase (UGT)1A1*28 and UGT1A1*6 polymorphisms. METHODS: This clinical trial included 115 patients receiving irinotecan combined with 5-fluorouracil plus 1-leucovorin (FOLFIRI) treatment. All patients consented to UGT1A1*28 and *6 gene polymorphism detection prior to chemotherapy. SXD were administered from 1 day prior to chemotherapy to 6 day post chemotherapy. Chemotherapy induced adverse reactions (neutropenia, diarrhea, nausea, vomiting, anorexia and infection) were recorded, and short-term effect of chemotherapy was evaluated regularly." RESULTS: A total of 50 patients had *1/*1 wild genotype, 58 patients had single allele variants with genotype *1/*6 or *1/*28, and 7 patients had two alleles variants with genotype *6/*6, *28/*28 or *61* 28. In *1/*6 or *1/*28 patients (high risk group),.9 patients (15.5%) developed I II grade diarrhea and no patient developed severe diarrhea; neutropenia occurred in 19 patients (32.8%) and only 3 patients (8.6%) developed sever neutropenia. There were no significant differences in any toxic effects (neutropenia, diarrhea, nausea, vomiting, anorexia or infection) between *6 or *28 variant patients (high risk group) and wild type patients. No sever toxicity was found in high risk two alleles variants patients (*6/*6, *6/*28 or *28/*28). No significant differences were observed between UGT1A1*6/*28 polymorphisms and clinical response of chemotherapy. CONCLUSION: SXD could significantly reduce irinotecan-induced hematological and gastrointestinal toxicities in UGT1A1*28 or *6 variant patients (high risk group), while this treatment didn't affect clinical response of chemotherapy. (C) 2017 JTCM. All rights reserved.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 50 条
  • [31] Commentary: Profiling of UGT1A1*6, UGT1A1*60, UGT1A1*93, and UGT1A1*28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
    Heydari, Mohammad Reza
    Fardaei, Majid
    FRONTIERS IN PEDIATRICS, 2020, 7
  • [32] Re:: UGT1A1*28 genotype and irinotecan-induced neutropenia:: Dose matters
    Ichikawa, Wataru
    Araki, Kazuhiro
    Fujita, Ken-Ichi
    Yamamoto, Wataru
    Endo, Hisashi
    Nagashima, Fumio
    Tanaka, Ryuhei
    Miya, Toshimichi
    Kodama, Keiji
    Sunakawa, Yu
    Narabayashi, Masaru
    Ando, Yuichi
    Akiyama, Yuko
    Kawara, Kaori
    Sasaki, Yasutsuna
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (03)
  • [33] UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
    Lei Cheng
    Ming Li
    Jing Hu
    Wei Ren
    Li Xie
    Zhan-Peng Sun
    Bao-Rui Liu
    Gen-Xing Xu
    Xiao-Liang Dong
    Xiao-Ping Qian
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 551 - 560
  • [34] UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians
    Cheng, Lei
    Li, Ming
    Hu, Jing
    Ren, Wei
    Xie, Li
    Sun, Zhan-Peng
    Liu, Bao-Rui
    Xu, Gen-Xing
    Dong, Xiao-Liang
    Qian, Xiao-Ping
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 551 - 560
  • [35] Polymorphisms of UGT1A1 are the Useful Predictive Markers for the Toxicity of Irinotecan
    Hazama, Shoichi
    Hinoda, Yuji
    Okayama, Naoko
    Sakamoto, Junichi
    Mishima, Hideyuki
    Oka, Masaaki
    TUMOR BIOLOGY, 2008, 29 : 20 - 20
  • [37] Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients
    Thu Nguyen, Cuc Thi
    Minh Thuy, Nguyen Thi
    Huong, Phung Thanh
    PHARMACOGENOMICS, 2024, 25 (10-11) : 469 - 477
  • [38] UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
    Iyer L.
    Das S.
    Janisch L.
    Wen M.
    Ramírez J.
    Karrison T.
    Fleming G.F.
    Vokes E.E.
    Schilsky R.L.
    Ratain M.J.
    The Pharmacogenomics Journal, 2002, 2 (1) : 43 - 47
  • [39] Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecaninduced toxicity in Chinese cancer patients
    Yan, Liang
    Wang, Xiao-fei
    Wei, Lu-man
    Nie, Ya-li
    Liu, Jing-yang
    Zhang, Li-rong
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (03) : 193 - 199
  • [40] Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese:: roles of UGT1A1*6 and*28
    Minami, Hironobu
    Sai, Kimie
    Saeki, Mayumi
    Saito, Yoshiro
    Ozawa, Shogo
    Suzuki, Kazuhiro
    Kaniwa, Nahoko
    Sawada, Jun-ichi
    Hamaguchi, Tetsuya
    Yamamoto, Noboru
    Shirao, Kuniaki
    Yamada, Yasuhide
    Ohmatsu, Hironobu
    Kubota, Kaoru
    Yoshida, Teruhiko
    Ohtsu, Atsushi
    Saijo, Nagahiro
    PHARMACOGENETICS AND GENOMICS, 2007, 17 (07): : 497 - 504